Shajini

A passionate learner and skilled writer, Shajini serves as a Content Writer at Synopulse, delivering clear and engaging content across biopharmaceuticals and MedTech. With an MBA from Arunachala College of Engineering for Women, Shajini brings a blend of analytical expertise and creativity to simplify complex topics into impactful articles and reports.

FDA Unveils Second Wave of National Priority Voucher Winners, Featuring Obesity Leaders Lilly and Novo Nordisk

by
FDA unveils second wave of National Priority Voucher winners, featuring obesity leaders Lilly and Novo Nordisk

Scientists and staff walk outside the U.S. Food and Drug Administration headquarters, representing the agency’s growing focus on regulatory innovation and public health priorities. (AI-generated for editorial illustration purposes.) FDA expands National Priority Voucher pilot with six new awardees, bringing total to 15 therapies The U.S. Food and Drug Administration (FDA) has announced a significant … Read more

Pfizer wins $10 billion bidding war for Metsera after competitive bidding with Novo Nordisk

by
Pfizer wins $10 billion bidding war for Metsera after competitive bidding with Novo Nordisk

Months of legal challenges, court rulings, and regulatory probes define the industry’s fiercest metabolic takeover fight Pfizer has signed a definitive agreement to acquire metabolic biotech Metsera, ending months of one of the most aggressive takeover battles in recent biopharma history. The deal concludes a dramatic contest with Novo Nordisk, which had initially secured Metsera’s … Read more

Dutch Healthcare Institute Limits Early Access to Obesity Drugs Amid Cost and Evidence Concerns

by
Dutch Healthcare Institute Limits Early Access to Obesity Drugs Amid Cost and Evidence Concerns

The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.

NextGen Gene Editing Breakthroughs Redefine Personalized Care

by
NextGen Gene Editing Breakthroughs Redefine Personalized Care

The New Frontier of Gene Editing: From Precision Tools to Personalized Therapies A new generation of programmable gene editing tools is pushing biotechnology toward an era of truly personalized medicine one in which therapies are tailored not only to specific diseases but to individual genetic profiles. As highlighted in a recent npj Biomedical Innovations feature … Read more